

64th Meeting of the National Cancer Institute (NCI) Director's Consumer Liaison Group (DCLG)

Barriers to Drug Development in Pediatric Cancer Research

National Institutes of Health (NIH) Campus
Building 31C, 6th Floor, Conference Room 6
Bethesda, Maryland

Friday, February 21, 2014

- 9:30 a.m. Welcome and Opening Remarks**
Amy Bulman, Acting Director, Office of Advocacy Relations, NCI
Max Wallace, Chair, DCLG
- 9:40 a.m. NCI Update**
John Czajkowski, Deputy Director for Management, NCI
- 10:00 a.m. The State of Pediatric Cancer Research**
Dr. John Maris, Director, Center for Childhood Cancer Research,
Children's Hospital of Philadelphia
Dr. Malcolm Smith, Associate Branch Chief for Pediatric Oncology,
Cancer Therapy Evaluation Program, NCI
Dr. Lee Helman, Scientific Director for Clinical Research,
Center for Cancer Research (CCR), NCI
- 11:30 a.m. Break**
- 12:00 p.m. Working Lunch and Panel Discussion: The Potential Role of the Pediatric Cancer Advocacy Community in Reducing Barriers to Drug Development**
Dr. Peter Adamson, Chief, Division of Clinical Pharmacology and Therapeutics,
Children's Hospital of Philadelphia
Nancy Goodman, Executive Director, Kids v Cancer
Dr. Gregory Reaman, Associate Director, Office of Oncology Drug Products,
Food and Drug Administration
Moderators: Dr. Lee Helman, Scientific Director for Clinical Research, CCR, NCI,
and David Arons, Senior Director of Public Policy, National Brain Tumor Society
- 1:30 p.m. Advancing Pediatric Cancer Research Through Advocacy**
Lisa Tichenor, QuadW
Maureen Lilly, Children's Cause for Cancer Advocacy
Ruth Hoffman, American Childhood Cancer Organization
Sarah Bogdan, American Cancer Society Cancer Action Network
Peter Mayberry, St. Baldrick's Foundation
Vickie Buenger, Coalition Against Childhood Cancer
- 3:00 p.m. Next Steps for the DCLG**
Max Wallace, Chair, DCLG
- 3:30 p.m. Working Group Discussion and New Business**
Max Wallace, Chair, DCLG
- 4:00 p.m. Adjourn**